Traders should monitor for topline results from PALISADE-4 expected within Q2 2026. A positive outcome could be a significant catalyst for the stock given the $23M market cap; a negative result would likely be bearish.
VTGN drugs
VTGN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 11 $0.6700entry
- T+1 · 6mo ago −7.46%α −7.33% · $0.6200
- T+5 · 6mo ago −10.45%α −10.36% · $0.6000
- T+20 · 5mo ago −19.40%α −19.10% · $0.5400
- T+60 · 3mo ago −55.67%α −60.06% · $0.2970
Price Chart
How similar events traded
Executive Summary
Vistagen announced the completion of the last patient visit in the randomized portion of its PALISADE-4 Phase 3 trial evaluating fasedienol nasal spray for social anxiety disorder. Topline results are expected in the second quarter of 2026. This is a routine clinical milestone with no financial data disclosed.
Key Facts
- Last patient completed last visit in randomized portion of PALISADE-4 Phase 3 trial.
- Topline results expected in Q2 2026.
- Open label extension (OLE) portion remains ongoing.
- FDA Fast Track designation for fasedienol in social anxiety disorder.
- Statistical analysis plan (SAP) refined to incorporate pre-IP SUDS as covariate; FDA had no comments.
Financial Impact
No financial data disclosed in the filing.
Risk Factors
- No guarantee of positive trial outcome despite SAP refinements.
- Previous PALISADE trials (1 and 3) have not been reported as positive.
- Stock may be volatile around topline data release.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-032935 |
| Document: pal-4lplvprex991.htm | 0001628280-26-032935 |
| Document: 0001628280-26-032935-index-headers.html | 0001628280-26-032935 |
| Document: 0001628280-26-032935-index.html | 0001628280-26-032935 |
| Document: 0001628280-26-032935.txt | 0001628280-26-032935 |
Track record
21 reports on VTGN
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
- Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers